China Bioanalysis Forum 2024 -- Gene therapy brings the promise of a one-time treatment option that will fix the errors in patient genetic coding. Recombinant viruses are highly efficient vehicles for in vivo gene delivery. Adeno-associated virus (AAV) is one of the most actively investigated delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Assessment of the neutralizing antibodies (NAbs) of AAV in patients prior to/after systemic gene therapy administration is an important consideration regarding efficacy and safety of the therapy.

• Download